UK markets closed

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
129.21+1.22 (+0.95%)
As of 11:34AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close127.99
Open127.39
Bid128.88 x 900
Ask128.93 x 800
Day's range126.78 - 129.23
52-week range99.14 - 133.10
Volume2,699,845
Avg. volume7,411,091
Market cap327.264B
Beta (5Y monthly)0.40
PE ratio (TTM)143.57
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.08 (2.41%)
Ex-dividend date17 Jun 2024
1y target estN/A
  • Yahoo Finance Video

    FDA approves Merck's pneumonia vaccine for adults

    The Food and Drug Administration (FDA) has approved Merck's (MRK) new vaccine to protect adults from pneumonia. Yahoo Finance's Anjalee Khemlani reports more on how the vaccine works as the pharmaceutical company awaits the Centers for Disease Control's (CDC) recommendation. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl

  • Benzinga

    Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment

    AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca

  • Zacks

    Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval

    Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.